Led · Seed · Aug 2020

Future Fields’ core product is the EntoEngine, a platform that uses genetically engineered fruit flies grown in simple containers to produce human recombinant proteins as an alternative to traditional stainless‑steel bioreactors. The company positions this approach as more scalable, cost‑effective and sustainable, claiming EntoEngine can create biomass 16–30× faster and generate proteins daily with the same footprint. Its product suite includes five human recombinant proteins used in wound healing, reproductive biology, muscle and breast milk development, and stem cell research. Future Fields has shipped its animal protein product to more than 60 companies over the past 18 months and says its team has doubled in size during the last year. The company is building its first production facility next to its corporate headquarters in Edmonton, Canada, which it expects will enable kilogram‑scale recombinant protein production in roughly 10,000 square feet. The seed extension announced will fund that facility buildout and broader product launches into research, cell therapies and biopharmaceutical markets. Future Fields is a cellular agriculture company based in Edmonton, Alberta, Canada. It was co-founded by Matthew Anderson-Baron, Jalene Anderson-Baron and Lejjy Gafour. Future Fields develops a cellular growth medium that lowers the cost of producing lab-grown meat. The company participated in Y Combinator's S20 cohort. Future Fields raised $2.2M in seed financing led by Bee Partners. The company intends to use the funds to expand operations and business reach. Future Fields builds a cell growth medium intended to drive down the cost of cultured meat production. The founders — Matt and Jalene Anderson-Baron and Lejjy Gafour — pivoted from making lab-grown chicken to commercializing their growth serum after early experiments in Alberta. The company says it genetically modifies an organism to produce specific growth factors but does not disclose the exact cell line or technical details. Future Fields has paid contracts, is leaving the Y Combinator accelerator, and plans to roll out initial pilot product lines for shipment within the next month. It can currently produce a few hundred liters of growth factor and aims to scale to tens of thousands of liters per month over the next year, targeting production costs of about $2–$3 per liter at scale. The team positions the product as a key piece for the cellular agriculture industry to move from discovery to commercialization.